Expertise in
24
conditions

Dr. Jia Y. Ruan

Hematology | Oncology
Lymphoma
520 E 70th St # 3, 
New York, NY 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Expertise in
24
conditions
Lymphoma
520 E 70th St # 3, 
New York, NY 

Overview

Jia Ruan is a Hematologist and an Oncologist practicing medicine in New York, New York.

Dr. Ruan is highly rated in 24 conditions, according to our data. Her clinical expertise encompasses Non-Hodgkin Lymphoma, Peripheral T-Cell Lymphoma, T-Cell Lymphoma, Bone Marrow Aspiration, and Bone Marrow Transplant.

She is actively involved in clinical research, co-authoring 105 peer reviewed articles and participating in 9 clinical trials. Dr. Ruan is currently accepting new patients.

Specialties

Hematology
Oncology

Licenses

Internal Medicine in NY

Hospital Affiliations

New York-Presbyterian Hospital

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Health First
  • HMO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
MetLife
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 5 Less Insurance Carriers -

Locations

Lymphoma
520 E 70th St # 3, New York, NY 10021

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

Phase II Multicenter Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma
Phase II Multicenter Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma
Enrollment Status: Recruiting
Publish Date: April 22, 2026
Intervention Type: Drug
Study Drug: Ruxolitinib
Study Phase: Phase 2
Phase II Study of Romidepsin Plus Lenalidomide for Patients With Previously Untreated PTCL
Phase II Study of Romidepsin Plus Lenalidomide for Patients With Previously Untreated PTCL
Enrollment Status: Completed
Publish Date: June 12, 2026
Intervention Type: Other, Drug
Study Drugs: Romidepsin, Lenalidomide
Study Phase: Phase 2
A Multiple-center Phase 2 Study of Acalabrutinib-Lenalidomide-Rituximab (ALR) With an Expansion Cohort of Acalabrutinib-Lenalidomide-Obinutuzumab (ALO) in Patients With Previous Untreated Mantle Cell Lymphoma
A Multiple-center Phase 2 Study of Acalabrutinib-Lenalidomide-Rituximab (ALR) With an Expansion Cohort of Acalabrutinib-Lenalidomide-Obinutuzumab (ALO) in Patients With Previous Untreated Mantle Cell Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: April 28, 2026
Intervention Type: Drug
Study Drugs: Acalabrutinib, Lenalidomide, Rituximab
Study Phase: Phase 2
A Randomized Phase II Trial of Myeloablative Versus Non-Myeloablative Consolidation Chemotherapy for Newly Diagnosed Primary CNS B-cell Lymphoma
A Randomized Phase II Trial of Myeloablative Versus Non-Myeloablative Consolidation Chemotherapy for Newly Diagnosed Primary CNS B-cell Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: January 30, 2026
Intervention Type: Drug, Procedure
Study Drugs: Carmustine, Cytarabine, Etoposide, Thiotepa, Granulocyte Colony-Stimulating Factor
Study Phase: Phase 2
A Phase 2 Multicenter Study of High Dose Chemotherapy With Autologous Stem Cell Transplant Followed by Maintenance Therapy With Romidepsin for the Treatment of T Cell Non-Hodgkin Lymphoma
A Phase 2 Multicenter Study of High Dose Chemotherapy With Autologous Stem Cell Transplant Followed by Maintenance Therapy With Romidepsin for the Treatment of T Cell Non-Hodgkin Lymphoma
Enrollment Status: Completed
Publish Date: October 09, 2025
Intervention Type: Other
Study Drugs: High Dose Chemotherapy, Autologous Stem Cell Transplant, Romidepsin
Study Phase: Phase 2
Phase II Trial of Response-Adapted Therapy Based on Positron Emission Tomography (PET) for Bulky Stage I and Stage II Classical Hodgkin Lymphoma (HL)
Phase II Trial of Response-Adapted Therapy Based on Positron Emission Tomography (PET) for Bulky Stage I and Stage II Classical Hodgkin Lymphoma (HL)
Enrollment Status: Completed
Publish Date: December 01, 2021
Intervention Type: Drug, Radiation
Study Drugs: Doxorubicin, Bleomycin, Vinblastine, Dacarbazine, Etoposide, Cyclophosphamide, Vincristine, Procarbazine, Prednisone
Study Phase: Phase 2
A Phase 2 Open Label Study to Investigate the Safety and Clinical Activity of Autologous EBV-specific T Cells (CMD-003) for the Treatment of Patients With EBV Positive Lymphomas
A Phase 2 Open Label Study to Investigate the Safety and Clinical Activity of Autologous EBV-specific T Cells (CMD-003) for the Treatment of Patients With EBV Positive Lymphomas
Enrollment Status: Terminated
Publish Date: March 26, 2019
Intervention Type: Biological
Study Phase: Phase 2
A Phase 2 Single Arm Study to Investigate the Efficacy of Autologous EBV-specific T-cells for the Treatment of Patients With Aggressive EBV Positive Extranodal NK/T-cell Lymphoma (ENKTCL)
A Phase 2 Single Arm Study to Investigate the Efficacy of Autologous EBV-specific T-cells for the Treatment of Patients With Aggressive EBV Positive Extranodal NK/T-cell Lymphoma (ENKTCL)
Enrollment Status: Terminated
Publish Date: March 13, 2019
Intervention Type: Biological
Study Phase: Phase 2
Oral Hepatitis C Treatment for Indolent Lymphoma (OPTImaL) Study
Oral Hepatitis C Treatment for Indolent Lymphoma (OPTImaL) Study
Enrollment Status: Terminated
Publish Date: January 08, 2019
Intervention Type: Drug
Study Phase: Phase 4
View 8 Less Clinical Trials

105 Total Publications

Recruitment Strategies, Challenges, and Gaps in Reaching Asian American Dementia Caregivers: A Scoping Review.
Recruitment Strategies, Challenges, and Gaps in Reaching Asian American Dementia Caregivers: A Scoping Review.
Journal: Journal of applied gerontology : the official journal of the Southern Gerontological Society
Published: July 29, 2026
Similar Doctors
Expertise in
34
conditions
Dr. Steven M. Horwitz
Hematology | Oncology
Expertise in
34
conditions
Dr. Steven M. Horwitz
Hematology | Oncology
Referral may be required

David H. Koch Center For Cancer Care At Memorial Sloan Kettering Cancer Center

530 E 74th St, 
New York, NY 
 (0.4 miles away)
646-535-8986
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Steven Horwitz is a Hematologist and an Oncologist practicing medicine in New York, New York. Dr. Horwitz is highly rated in 34 conditions, according to our data. His clinical expertise encompasses Peripheral T-Cell Lymphoma, T-Cell Lymphoma, Non-Hodgkin Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Horwitz is currently accepting new patients.

Expertise in
27
conditions
Dr. Gilles A. Salles
Hematology | Oncology
Expertise in
27
conditions
Dr. Gilles A. Salles
Hematology | Oncology
Referral may be required

David H. Koch Center For Cancer Care At Memorial Sloan Kettering Cancer Center

530 E 74th St, 
New York, NY 
 (0.4 miles away)
929-298-9410
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Gilles Salles is a Hematologist and an Oncologist practicing medicine in New York, New York. Dr. Salles is highly rated in 27 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma, Bone Marrow Transplant, and Splenectomy. Dr. Salles is currently accepting new patients.

Expertise in
31
conditions
Dr. Alison J. Moskowitz
Hematology | Oncology
Expertise in
31
conditions
Dr. Alison J. Moskowitz
Hematology | Oncology
Referral may be required

David H. Koch Center For Cancer Care At Memorial Sloan Kettering Cancer Center

530 E 74th St, 
New York, NY 
 (0.4 miles away)
332-456-0508
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Alison Moskowitz is a Hematologist and an Oncologist practicing medicine in New York, New York. Dr. Moskowitz is highly rated in 31 conditions, according to our data. Her clinical expertise encompasses Hodgkin Lymphoma, T-Cell Lymphoma, Peripheral T-Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Moskowitz is currently accepting new patients.

Frequently Asked Questions about Dr. Jia Y. Ruan

How do I make an appointment with Dr. Jia Y. Ruan?

You can book an appointment with Dr. Jia Y. Ruan by calling their office at 347-380-4390. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Jia Y. Ruan a top-rated expert for Non-Hodgkin Lymphoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Jia Y. Ruan is classified as an Elite expert for Non-Hodgkin Lymphoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Jia Y. Ruan specialize in?

While Dr. Jia Y. Ruan is a Hematology, they have specific expertise in Non-Hodgkin Lymphoma, Peripheral T-Cell Lymphoma, and T-Cell Lymphoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Jia Y. Ruan participate in research or clinical trials?

Yes. Dr. Jia Y. Ruan has published 105 articles and abstracts on conditions like Non-Hodgkin Lymphoma. You can view a list of Dr. Jia Y. Ruan's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Jia Y. Ruan accept my insurance?

Dr. Jia Y. Ruan accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 347-380-4390 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Ruan's expertise for a condition
ConditionClose
View All 8 Distinguished Conditions
View All 12 Advanced Conditions
View All 29 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile